Pfizer projects 2025 revenue of $61.0-$64.0 billion and adjusted EPS of $2.80-$3.00, anticipating 10-18% operational EPS growth from 2024 baseline. The company expects COVID-19 product revenues in 2025 to be largely consistent with 2024, excluding $1.2 billion in non-recurring 2024 Paxlovid revenue.The guidance factors in a $1 billion negative impact from Medicare Part D changes and approximately $0.6 billion impact from generic competition. Pfizer achieved its $4 billion cost savings goal through 2024 and targets an additional $500 million in 2025. The company's Manufacturing Optimization Program aims to improve gross margins, with initial net cost savings expected in late 2025.Pfizer reaffirmed its 2024 guidance and emphasized its strong product portfolio and pipeline. CEO Albert Bourla expressed confidence in the company's strategic roadmap and ability to deliver shareholder value, citing disciplined execution and focused financial management as key drivers for future success.

Pfizer projects 2025 revenue of $61.0-$64.0 billion and adjusted EPS of $2.80-$3.00, anticipating 10-18% operational EPS growth from 2024 baseline. The company expects COVID-19 product revenues in 2025 to be largely consistent with 2024, excluding $1.2 billion in non-recurring 2024 Paxlovid revenue.The guidance factors in a $1 billion negative impact from Medicare Part D changes and approximately $0.6 billion impact from generic competition. Pfizer achieved its $4 billion cost savings goal through 2024 and targets an additional $500 million in 2025. The company's Manufacturing Optimization Program aims to improve gross margins, with initial net cost savings expected in late 2025.Pfizer reaffirmed its 2024 guidance and emphasized its strong product portfolio and pipeline. CEO Albert Bourla expressed confidence in the company's strategic roadmap and ability to deliver shareholder value, citing disciplined execution and focused financial management as key drivers for future success.